c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

New England Journal of Medicine

Volumn 330, Issue 18, 1994, Pages 1260-1266

  Muss, Hyman B ^a   Thor, Ann D ^b   Berry, Donald A ^c   Kute, Timothy ^a   Liu, Edison T ^d   Koerner, Frederick ^b   Cirrincione, Constance T ^c   Budman, Daniel R ^e   Wood, William C ^f   Barcos, Maurice ^g   Henderson, I Craig ^h  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Cancer and Leukemia Group B Statistical Center   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^f EMORY UNIVERSITY   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; ONCOPROTEIN; PROGESTERONE; PROTEIN P53; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA CONTENT; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONCOGENE; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DNA, NEOPLASM; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; S PHASE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0028354305     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199405053301802     Document Type: Article

References (49)

1. Carter CL, Allen C, Henson DE Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-187
2. Identification of breast cancer patients with high risk of early recurrence after radical mastectomyII. Clinical and pathological correlations: a report of the Primary Therapy of Breast Cancer Study Group. Cancer 1978; 42: 2809-2826
3. Henson DE, Ries L, Freedman LS, Carriaga M Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer: the basis for a prognostic index. Cancer 1991; 68: 2142-2149
4. Osborne CK. Receptors. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast diseases. 2nd ed. Philadelphia: J.B. Lippincott, 1991:301-25.
5. McGuire WL, Clark GM Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992; 326: 1756-1761
6. Muss HB, Kute TE. Flow cytometry in the management of breast cancer. In: Ragaz J, Ariel IM, eds. High-risk breast cancer: diagnosis. Berlin, Germany: Springer-Verlag, 1989:103-19.
7. Hedley DW, Friedlander ML, Taylor IW Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. Cytometry 1985; 6: 327-333
8. Kute TE, Gregory B, Galleshaw J, Hopkins M, Buss D, Case D How reproducible are flow cytometry data from paraffin-embedded blocks? Cytometry 1988; 9: 494-498
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182
10. Lupu R, Colomer R, Kannan B, Lippman ME Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses. Proc Natl Acad Sci U S A 1992; 89: 2287-2291
11. Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J Epidermal growth factor receptor and other oncogenes as prognostic markers. Monogr Natl Cancer Inst 1992; 11: 181-187
12. Barnes DM, Meyer JS, Gonzalez JG, Gullick WJ, Millis RR Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. Breast Cancer Res Treat 1991; 18: 11-17
13. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49: 650-655
14. Slamon DJ, Godolphin W, Jones LA, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712
15. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120-1128
16. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 1991; 63: 444-446
17. Paik S, Hazan R, Fisher ER, Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103-112
18. Toikkanen S, Helin H, Isola J, Joensuu H Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992; 10: 1044-1048
19. Deppert W, Buschhausen-Denker G, Patschinsky T, Steinmeyer K Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. II. Requirement for cell cycle progression. Oncogene 1990; 5: 1701-1706
20. Kern SE, Kinzler KW, Bruskin A, Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252: 1708-1711
21. Montenarh M Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53. Crit Rev Oncog 1992; 3: 233-256
22. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A 1992; 89: 4495-4499
23. Callahan R, Cropp CS, Merlo GR, Liscia DS, Cappa APM, Lidereau R Somatic mutations and human breast cancer: a status report. Cancer 1992; 69: Suppl: 1582-1588
24. Thor AD, Moore DH II, Edgerton SM, Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-855
25. Isola J, Visakorpi T, Holli K, Kallioniemi OP Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992; 84: 1109-1114
26. Allred DC, Clark GM, Elledge R, Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206
27. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71
28. Fisher ER, Redmond C, Fisher B Pathologic findings from the National Surgical Adjuvant Breast Project. VIII. Relationship of chemotherapeutic responsiveness to tumor differentiation. Cancer 1983; 51: 181-191
29. Fisher B, Fisher ER, Redmond C Ten year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 1986; 4: 929-941
30. Zambetti M, Bonadonna G, Valagussa P, Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients. Monogr Natl Cancer Inst 1992; 11: 77-83
31. O'Reilly SM, Camplejohn RS, Millis RR, Rubens RD, Richards MA Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 1990; 26: 1035-1038
32. Wood WC, Budman DR, Korzun AH, Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253-1259
33. Black MM, Opler SR, Speer FD Survival in breast cancer cases in relation to the structure of the primary tumor and regional lymph nodes. Surg Gynecol Obstet 1955; 100: 543-551
34. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-1335
35. Baisch H, Gohde W, Linden WA Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys 1975; 12: 31-39
36. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992; 7: 1027-1032
37. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989; 320: 627-633
38. Peto R, Pike MC, Armitage P, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585-612
39. Peto R, Pike MC, Armitage P, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39
40. Zar JH. Biostatistical analysis. Englewood Cliffs, N.J.: Prentice-Hall, 1974.
41. Cox DR Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220
42. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 1989; 81: 1383-1387
43. O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 1992; 28: 681-683
44. Sulkes A, Livingston RB, Murphy WK Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 1979; 62: 513-515
45. Allred DC, Clark GM, Tandon AK, HER2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605
46. Gusterson BA, Gelber RD, Goldhirsch A, Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-1056
47. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL Topoisomerase IIalpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993; 8: 933-938
48. Tsai C-M, Chang K-T, Perng R-P, Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993; 85: 897-901
49. Eddy DM High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 1992; 10: 657-670 [Erratum, J Clin Oncol 1992;10:1655-8.]